JMP Securities Remains a Buy on Neuronetics (STIM)

By Jason Carr

In a report released today, David Turkaly from JMP Securities reiterated a Buy rating on Neuronetics (STIMResearch Report), with a price target of $12.00. The company’s shares closed last Wednesday at $4.83, close to its 52-week low of $4.78.

According to, Turkaly is a 4-star analyst with an average return of 12.2% and a 51.7% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as OrthoPediatrics, Avanos Medical, and Globus Medical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neuronetics with a $13.00 average price target, a 177.8% upside from current levels. In a report issued on October 12, Piper Sandler also maintained a Buy rating on the stock with a $12.00 price target.

See today’s best-performing stocks on TipRanks >>

Neuronetics’ market cap is currently $168.4M and has a P/E ratio of -6.50. The company has a Price to Book ratio of 1.70.

Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of STIM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Neuronetics, Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.